Early detection and intervention evaluation for people at high-risk of psychosis-2 (EDIE-2): Trial rationale, design and baseline characteristics

Early Intervention in Psychiatry

Volumn 5, Issue 1, 2011, Pages 24-32

  Morrison, Anthony P ^a,d   Stewart, Suzanne L K ^a   French, Paul ^d   Bentall, Richard P ^e   Birchwood, Max ^f   Byrne, Rory ^d   Davies, Linda M ^b   Fowler, David ^h   Gumley, Andrew I ⁱ   Jones, Peter B ^j   Lewis, Shôn W ^c   Murray, Graham K ^j   Patterson, Paul ^g   Dunn, Graham ^b  

^a School of Psychological Sciences   (United Kingdom)

^b School of Medicine   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d GREATER MANCHESTER MENTAL HEALTH NHS FOUNDATION TRUST   (United Kingdom)

^e BANGOR UNIVERSITY   (United Kingdom)

^f UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^g BIRMINGHAM AND SOLIHULL MENTAL HEALTH NHS FOUNDATION TRUST   (United Kingdom)

^h UNIVERSITY OF EAST ANGLIA   (United Kingdom)

ⁱ UNIVERSITY OF GLASGOW   (United Kingdom)

^j UNIVERSITY OF CAMBRIDGE   (United Kingdom)

more..

Author keywords

At risk mental state; Cognitive therapy; Early intervention; Prodrome; Psychosis

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL (TOPIC); COGNITIVE THERAPY; DISEASE COURSE; EARLY DIAGNOSIS; EARLY INTERVENTION; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT MONITORING; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SINGLE BLIND PROCEDURE; THERAPY EFFECT;

ADOLESCENT; ADULT; COGNITIVE THERAPY; DATA COLLECTION; EARLY DIAGNOSIS; HUMANS; MALE; PSYCHOTIC DISORDERS;

EID: 79251553465     PISSN: 17517885     EISSN: 17517893     Source Type: Journal    
DOI: 10.1111/j.1751-7893.2010.00254.x     Document Type: Article

References (36)

1. Morrison AP, French P, Walford L etal. Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial. Br J Psychiatry 2004; 185: 291-97.
2. Miller P, Lawrie SM, Hodges A, Clafferty R, Cosway R, Johnstone EC. Genetic liability, illicit drug use, life stress and psychotic symptoms: preliminary findings from the Edinburgh study of people at high risk for schizophrenia. Soc Psychiatry Psychiatr Epidemiol 2001; 36: 338-42.
3. Klosterkotter J, Hellmich M, Steinmeyer EM, Schultze-Lutter F. Diagnosing schizophrenia in the prodromal stage. Arch Gen Psychiatry 2001; 58: 158-64.
4. van Os J, Hanssen M, Bijl RV, Vollebergh W. Prevalence of psychotic disorder and community level of psychotic symptoms - an urban-rural comparison. Arch Gen Psychiatry 2001; 58: 663-8.
5. Yung AR, McGorry PD. The prodromal phase of first episode psychosis: past and current conceptualisations. Schizophr Bull 1996; 22: 353-70.
6. Yung AR, Phillips LJ, McGorry PD etal. Prediction of psychosis - a step towards indicated prevention of schizophrenia. Br J Psychiatry 1998; 172: 14-20.
7. Cole E, Leavey G, King M, Johnson-Sabine E, Hoar R. Pathways to care for patients with a first episode of psychosis. Br J Psychiatry 1995; 167: 770-6.
8. Skeate A, Jackson C, Birchwood M, Jones C. Duration of untreated psychosis and pathways to care in first-episode psychosis: investigation of help-seeking behaviour in primary care. Br J Psychiatry 2002; 181 (Suppl. 43): S73-7.
9. McGlashan TH, Zipursky RB, Perkins D etal. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 2006; 163: 790-9.
10. McGorry PD, Yung AR, Phillips LJ etal. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 2002; 59: 921-8.
11. Dorph-Petersen K-A, Pierri JN, Perel JM etal. The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys. Neuropsychopharmacology 2005; 30: 1649-61.
12. Bentall RP, Morrison AP. More harm than good: the case against using antipsychotic drugs to prevent severe mental illness. J Ment Health 2002; 11: 351-65.
13. Cornblatt BA, Lencz T, Kane JM. Treatment of the schizophrenia prodrome: is it presently ethical? Schizophr Res 2001; 51: 31-8.
14. Morrison AP, Bentall RP, French P etal. Randomised controlled trial of early detection and cognitive therapy for preventing transition to psychosis in high-risk individuals: study design and interim analysis of transition rate and psychological risk factors. Br J Psychiatry 2002; 181: s78-s84.
15. Gumley AI, O'Grady M, McNay L, Reilly J, Power K, Norrie J. Early intervention for relapse in schizophrenia: results of a 12-month randomised controlled trial of cognitive behaviour therapy. Psychol Med 2003; 33: 419-31.
16. Kuipers E, Garety P, Fowler D etal. The London-East Anglia randomised controlled trial of cognitive-behaviour therapy for psychosis I: effects of the treatment phase. Br J Psychiatry 1997; 171: 319-27.
17. Tarrier N, Yusupoff L, Kinney C etal. A randomized controlled trial of intense cognitive behaviour therapy for chronic schizophrenia. Br Med J 1998; 317: 303-7.
18. Sensky T, Turkington D, Kingdon D etal. A randomized controlled trial of cognitive-behavioral therapy for persistent symptoms in schizophrenia resistant to medication. Arch Gen Psychiatry 2000; 57: 165-72.
19. Clark DM. Anxiety disorders: why they persist and how to treat them. Behav Res Ther 1999; 37 (Suppl. 1): 5-27.
20. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-76.
21. Morrison AP, French P, Parker S etal. Three-year follow-up of a randomized controlled trial of cognitive therapy for the prevention of psychosis in people at ultrahigh risk. Schizophr Bull 2007; 33: 682-7.
22. Yung AR, Yuen HP, McGorry PD etal. Mapping the onset of psychosis: the comprehensive assessment of at-risk mental states. Aust N Z J Psychiatry 2005; 39: 964-71.
23. Ainsworth JD, Harper RS. The PsyGrid Experience: using web services in the study of schizophrenia. Int J Healthc Inf Syst Inform 2007; 2: 1-20.
24. Morrison AP. The interpretation of intrusions in psychosis: an integrative cognitive approach to hallucinations and delusions. Behav Cogn Psychoth 2001; 29: 257-76.
25. French P, Morrison AP. Cognitive Therapy for People at High-Risk of Psychosis. London: Wiley, 2004.
26. Blackburn IM, James I, Milne D etal. The revised cognitive therapy scale (CTS-R): psychometric properties. Behav Cogn Psychother 2001; 29: 431-46.
27. Bell K, Startup M, French P, Morrison AP, Bucci S, Fowler D. Therapist treatment adherance in CBT for people at ultra-high risk for psychosis: development of a new rating scale. Early Interv Psychiatry 2008; 2 (Suppl. 1): A16.
28. Evans MD, Piasecki JM, Kriss MR, Hollon SD. Raters' Manual for the Collaborative Study Psychotherapy Rating Scale - Form 6. Minneapolis: University of Minnesota and the St. Paul-Ramsey Medical Center, 1984; Available from the U. S. Department of Commerce, National Technical Information Service, Springfield VA 22161.
29. Elkin I, Shea T, Watkins JT etal. National Institute of Mental Health Treatment of Depression Collaborative Research Program: general effectiveness of treatments. Arch Gen Psychiatry 1998; 46: 971-82.
30. Rollinson R, Smith B, Steel C etal. Measuring adherence and competence in CBT for psychosis: a psychometric analysis of an adherence scale. Behav Cogn Psychother 2008; 36: 163-78.
31. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition - Text Revision. Washington, D.C.: Author, 2000.
32. Beck AT, Guth D, Steer RA, Ball R. Screening for major depression disorders in medical inpatients with the Beck Depression Inventory for Primary Care. Behav Res Ther 1997; 35: 785-91.
33. Mattick RP, Clarke JC. Development and validation of measures of social phobia scrutiny fear and social interaction anxiety. Behav Res Ther 1998; 36: 455-70.
34. Oliver JP, Huxley PJ, Priebe S, Kaiser W. Measuring the quality of life of severely mentally ill people using the Lancashire Quality of Life Profile. Soc Psychiatry Psychiatr Epidemiol 1997; 32: 76-83.
35. Phillips LJ, Nelson B, Yuen HP etal. Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: study design and baseline characteristics. Aust N Z J Psychiatry 2009; 43: 818-29.
36. Yung AR, Yuen HP, Berger G etal. Declining transition rate in ultra high risk (prodromal) services: dilution or reduction of risk? Schizophr Bull 2007; 33: 673-81.